SCHEMBL509097

SCHEMBL509097

Cc1cccc(-c2cc3ccc(C)cc3c(N)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.50
ADORA2A P29274 1/20 0.49
ADORA1 P30542 1/20 0.49
RAB9A P51151 2/20 0.47
MAP4K4 O95819 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HEXA P06865 1/20 0.42
HEXB P07686 1/20 0.42
NPC1 O15118 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATR Q13535 1/20 0.42
IDO1 P14902 1/20 0.41
METAP2 P50579 1/20 0.41
TLR8 Q9NR97 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509539 0.87 XDH (0.50) XDHADORA2AADORA1RAB9AMAP4K4
SCHEMBL509138 0.86 SCN2A (0.48) ADORA2AADORA1RAB9AMAP4K4ALDH1A1
SCHEMBL508363 0.82 CYP1A2 (0.50) ADORA2AADORA1RAB9AALDH1A1NPC1
SCHEMBL508777 0.81 RAD52 (0.55) XDHADORA2AADORA1RAB9AALDH1A1
SCHEMBL510204 0.78 RAD52 (0.49) ADORA2AADORA1RAB9AALDH1A1NPC1
SCHEMBL509858 0.77 SYK (0.56) RAB9AALDH1A1NPC1SMN1; SMN2IDO1
SCHEMBL509124 0.77 NPC1 (0.47) ADORA2AADORA1RAB9AALDH1A1NPC1
SCHEMBL509116 0.76 DHFR (0.46) ADORA2ARAB9AALDH1A1HEXAHEXB
SCHEMBL508708 0.76 ADORA1 (0.51) ADORA2AADORA1RAB9AALDH1A1NPC1
SCHEMBL509201 0.75 RAD52 (0.49) ADORA2AADORA1ALDH1A1IDO1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 XDH 308/4885ADORA2A 1444/4885ADORA1 2974/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 XDH 308/4885ADORA2A 1444/4885ADORA1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.